Plasma Scientific Spółka z Ograniczoną Odpowiedzialnością (KRS 0000893092, NIP 8952229493) is a Polish company, headquartered in Wrocław, Dolnośląskie voivodeship. Plasma Scientific operates in: Scientific research and development (PKD 72.10.Z). Industry: Research and development. The company has been listed in the National Court Register since April 7, 2021. Plasma Scientific's most recently reported net revenue was 0 PLN for 2024.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Plasma Scientific
Identity
- Name
- Plasma Scientific Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- Limited Liability Company (LLC)
- Founded
- April 7, 2021
- Registry status as of
- July 3, 2026
- Latest entry
- July 3, 2026
- Founding act
- 02.04.2021 R.
Articles of association history (3)
- April 2, 2021: 02.04.2021 R.
- August 25, 2023: 25.08.2023 R., NOTARIUSZ ADAM BILIŃSKI, KANCELARIA NOTARIALNA WE WROCŁAWIU, REP. A NR 2739/2023, UCHYLENIE DOTYCHCZASOWEGO TEKSTU UMOWY SPÓŁKI I UCHWALENIE NOWEGO BRZMIENIA
- February 4, 2026: 2.04.2026 R., NOTARIUSZ ADAM BILIŃSKI, KANCELARIA NOTARIALNA WE WROCŁAWIU, REP. A NR 1112/2026, ZMIENIONO PAR. 4, PAR. 5, PAR. 6 UMOWY SPÓŁKI
Activities
Other activities
Address and contact
- Address
- UL. BIERUTOWSKA, 57-59, 17, 51-317, WROCŁAW, POLSKA
- Voivodeship
- DOLNOŚLĄSKIE
- District
- WROCŁAW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-58231-72358-CBTCH-12
Risk and payment profile - Plasma Scientific
Credibility rating
54.6 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
7
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/5 yrs
Board changes
3
3/5 yrs
PKD changes
1
1/5 yrs
Name changes
0
0/5 yrs
Data from 5 years of registry activity.
Credibility history
Payment reliability score from 2021–2024
Current: D (55/100)
Trend: stable (0.0 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2021–2024
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Plasma Scientific
Founded
April 7, 2021
5 years in operation
Legal form
Limited Liability Company (LLC)
Registry: RejP
Headquarters
WROCŁAW
DOLNOŚLĄSKIE
Primary PKD
72.10.Z
Scientific research and development
Share capital
8.8 K PLN
162 shares total
Shareholders
3
shareholders
Board
1 person
Proxies: 1
Filed years
4 years
2021–2024
Registry entries
18
latest: July 3, 2026
Revenue
0 PLN
2024
Net profit
0 PLN
2024
Assets
5.0 K PLN
2024
Equity
5.0 K PLN
2024
Board and connected people - Plasma Scientific
People holding roles at Plasma Scientific according to the Polish National Court Register. Follow a name for that person's full profile and their other companies.
- Jaromir KawęckiPresident of the board
- Paweł Piotr ModrzyńskiPresident of the board, Shareholder, Commercial proxy
- Marcin Lech WielebskiBoard member, Shareholder, Commercial proxy
Directories and rankings for this location
Public procurement
Trademarks
Reviews
Rate business credibility - Plasma Scientific.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.